Dendritic cell density and activation status of tumour-infiltrating lymphocytes in metastatic human melanoma: Possible implications for sentinel node metastases

Melanoma Research

Volumn 13, Issue 3, 2003, Pages 263-269

  Barbour, Angela H ^a   Coventry, Brendon J ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Dendritic cells; Immunity; Lymph nodes; Lymphocyte activation; Lymphocyte transformation; Melanoma; Neoplasm metastasis

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR; RECEPTOR SUBUNIT;

ARTICLE; B LYMPHOCYTE; CANCER GRADING; CELL ACTIVATION; CELL ACTIVITY; CELL DENSITY; CELL INFILTRATION; CONTROLLED STUDY; DENDRITIC CELL; FUNCTIONAL ASSESSMENT; HEALTH STATUS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; IMMUNE RESPONSE; LYMPH NODE METASTASIS; LYMPHOCYTE ACTIVATION; MACROPHAGE; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENTINEL LYMPH NODE; T LYMPHOCYTE; TUMOR CELL;

DENDRITIC CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MELANOMA; SENTINEL LYMPH NODE BIOPSY; T-LYMPHOCYTE SUBSETS;

EID: 0038177911     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200306000-00007     Document Type: Article

References (32)

1. Mukherji B, Chakraborty NG. Immunobiology and immunotherapy of melanoma. Curr Opin Oncol 1995; 7:175-184.
2. Hersey P. Melanoma peptides as vaccines. Today's Life Science 1996; April:34-38.
3. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994; 86:1159-1166.
4. thor Straten P, Becker JC, Guldberg P, Zeuthen J. In situ T cells in melanoma. Cancer Immunol Immunother 1999; 34:386-395.
5. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumours from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74:181-273.
6. Cochran AJ, Pihl E, Wen D, Hoon DSB, Korn EL. Zoned immune suppression of lymph nodes draining malignant melanoma: histologic and immunohistologic studies. J Natl Cancer Inst 1987; 87:399-405.
7. Cochran AJ, Morton DL, Stern S, Lana AM, Essner R, Wen D. Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol 2001; 14:604-608.
8. Farzad Z, Cochran AJ, McBride WH, Gray JD, Wong V, Morton DL. Lymphocyte subset alterations in nodes regional to human melanoma. Cancer Res 1990; 50:3585-3588.
9. Farzad Z, McBride WH, Ogbechi H, Asnong-Holthoff C, Morton DL, Cochran AJ. Lymphocytes from lymph nodes at different distances from human melanoma vary in their capacity to inhibit/enhance tumour cell growth in vitro. Melanoma Res 1997; 7 (suppl 2):S59-65.
10. Hoon DSB, Korn EL, Cochran AJ. Variations in functional immunocompetence of individual tumour-draining lymph nodes in humans. Cancer Res 1987; 47:1740-1744.
11. Essner R, Kojima M. Surgical and molecular approaches to the sentinel lymph nodes. Ann Surg Oncol 2001; 8 (suppl 9):31S-34S.
12. Leong SP, Peng M, Zhou YM, Vaquerano JE, Chang JW. Cytokine profiles of sentinel lymph nodes draining the primary melanoma. Ann Surg Oncol 2002; 9:82-87.
13. Cotner T, Williams JM, Christenson L, Shapiro HM, Strom TB, Strominger J. Simultaneous flow cytometric analysis of human T cell activation antigen expression and DNA content. J Exp Med 1983; 157:461-472.
14. Williams JM, Kelley VE, Kirkman RL, Tilney NL, Shapiro ME, Murphy JR, Strom TB. T cell activation antigens: therapeutic implications. Immunol Invest 1987-1988; 16:687-723.
15. Fischer WH, thor Straten P, Terheyden P, Becker JC. Function and dysfunction of CD4+ T cells in the immune response to melanoma. Cancer Immunol Immunother 1999; 48:363-370.
16. Seo N, Tokura Y, Furukawa F, Takigawa M. Down-regulation of tumor-icidal NK and NK T cell activities by MHC Kb molecules expressed on Th2-type gammadelta T and alphabeta T cells coinfiltrating in early B16 melanoma lesions. J Immunol 1998; 161:4138-4145.
17. Coventry BJ, Weeks SC, Heckford SE, Sykes PJ, Bradley J, Skinner JM. Lack of IL-2 cytokine expression despite IL-2 messenger RNA transcription in tumour-infiltrating lymphocytes in primary human breast carcinoma. J Immunol 1996; 156:3486-3492.
18. Lopez CB, Rao TD, Feiner H, Shapiro R, Marks JR, Frey AB. Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumour-infiltrating lymphocytes. Cell Immunol 1998; 190:141-155.
19. Enk AH, Jonuleit H, Saloga J, Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 1997; 73:309-316.
20. Brady MS, Eckels DD, Lee F, Ree SY, Lee JS. Cytokine production by CD4+ T-cells responding to antigen presentation by melanoma cells. Melanoma Res 1999; 9:173-180.
21. Goedegebuure PS, Lee KY, Matory YL, Peoples GE, Yoshino I, Eberlein TJ. Classification of CD4+ T helper cell clones in human melanoma. Cell Immunol 1994; 156:170-179.
22. McMillan DN, Kemohan NM, Flett ME, Heys SD, Deehan DJ, Sewell HF, et al. Interleukin 2 receptor expression and interleukin 2 localisation in human solid tumour cells in situ and in vitro: evidence for a direct role in the regulation of tumour cell proliferation. Int J Cancer 1995; 60:766-772.
23. Alileche A, Plaisance S, Han DS, Rubinstein E, Mingari C, Bellomo R, et al. Human melanoma cell line M14 secretes a functional interleukin 2. Oncogene 1993; 8:1791-1796.
24. Lotze MT, Custer MC, Sharrow SO, Rubin LA, Nelson DL, Rosenberg SA. In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res 1987; 47:2188-2195.
25. Beverly B, Kang SM, Lenardo MJ, Schwartz RH. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int Immunol 1992; 4:661-671.
26. Dummer W, Bastian BC, Ernst N, Schanzle C, Schwaaf A, Brocker EB. Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer 1996; 66:607-610.
27. Sato T, McCue P, Masuoka K, Salwen S, Lattime EC, Mastrangelo MJ, Berd D. Interleukin 10 production by human melanoma. Clin Cancer Res 1996; 2:1383-1390.
28. Becker Y. Anticancer role of dendritic cells (DC) in human and experimental cancers - a review. Anticancer Res 1992; 12:511-520.
29. Hillenbrand EE, Neville AM, Coventry BJ. Immunohistochemical localisation of CD1a positive putative dendritic cells in human breast tumours. Br J Cancer 1999; 79:940-944.
30. Coventry BJ. CD1a positive putative tumour infiltrating dendritic cells in human breast cancer. Anticancer Res 1999; 19:3183-3188.
31. Bröcker EB, Zwadlo G, Holzmann B, Macher E, Sorg C. Inflammatory cell infiltrates in human melanoma at different stages of tumour progression. Int J Cancer 1988; 41:562-567.
32. Simony J, Rossi JF, Shishehian B, Ursule E, Radal M, Pujol H. Characterization of proliferative cells in malignant melanomas and their inflammatory infiltrates. Cancer Detect Prev 1991; 15:183-187.